Based in London, Farringdon, Belluscura was founded in 2015 to develop proprietary oxygen enrichment technology to improve health outcomes for COPD patients and more favorable economic outcomes for patients, providers, and insurance companies. Their disruptive treatment platforms can be adapted and applied in a wide range of markets beyond those traditionally applied to a single product or product line. With North American headquarters in Texas, Belluscura is dedicated to positively impacting millions of people worldwide through their patented oxygen enrichment technologies applied across a range of treatment possibilities.